UBS remains bullish on Inspire Medical after Lilly’s OSA results

UBS analyst Danielle Antalffy remains bullish on Inspire Medical (INSP), and sees Eli Lilly’s (LLY) top-line SURMOUNT-OSA readout as right in line with expectations for apnea-hypopnea index reduction and the removal of an overhang. While the results likely support labeling for tirzepatide in treatment of obstructive sleep apnea, UBS does not see a near-term or even mid- to-long impact to Inspire fundamentals and sees any share weakness as a good buying opportunity, the analyst tells investors in a research note. UBS made no change to its Buy rating or $265 price target on Inspire Medical.